RESOLVING THE LEDGER
This is one outlet's own report from STAT — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 1 sources
Greg Verdine is having a very good year.
The scientist-turned-biotech entrepreneur has been basking in the knowledge that the science he had tried to propel forward nearly 15 years ago may have changed the landscape for pancreatic cancer patients .
His more recent ventures are taking off. One, Parabilis Medicines, went public in June in one of the industry’s largest IPOs in recent years. The other, LifeMine, has raised $263 million, it announced Thursday, enough to advance a drug that Verdine believes could make organ transplants more viable and potentially help people with autoimmune conditions.
Continue to STAT+ to read the full story…
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.